Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Jul 29, 2018
Open Peer Review Period: Jul 31, 2018 - Aug 30, 2018
Date Accepted: Oct 8, 2018
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Mobile-Based Oral Chemotherapy Adherence–Enhancing Interventions: Scoping Review

Skrabal Ross X, Gunn KM, Patterson P, Olver I

Mobile-Based Oral Chemotherapy Adherence–Enhancing Interventions: Scoping Review

JMIR Mhealth Uhealth 2018;6(12):e11724

DOI: 10.2196/11724

PMID: 30578182

PMCID: 6320412

Mobile-Based Oral Chemotherapy Adherence–Enhancing Interventions: Scoping Review

  • Xiomara Skrabal Ross; 
  • Kate M Gunn; 
  • Pandora Patterson; 
  • Ian Olver

ABSTRACT

Background:

Adherence to oral chemotherapy is crucial to maximize treatment outcomes and avoid health complications in cancer patients. Mobile phones are widely available worldwide, and evidence that this technology can be successfully employed to increase medication adherence for the treatment of other chronic diseases (eg, diabetes) is well established. However, the extent to which there is evidence that mobile phone–based interventions improve adherence to oral chemotherapy is unknown.

Objective:

This scoping review aims to explore what is known about mobile phone–delivered interventions designed to enhance adherence to oral chemotherapy, to examine the reported findings on the utility of these interventions in increasing oral chemotherapy adherence, and to identify opportunities for development of future interventions.

Methods:

This study followed Arksey and O’Malley’s scoping review methodological framework.

Results:

The review search yielded 5 studies reporting on 4 interventions with adults (aged >18 years) diagnosed with diverse cancer types. All interventions were considered acceptable, useful, and feasible. The following themes were evident: text messages and mobile apps were the main methods of delivering these interventions, the 2 most commonly employed oral chemotherapy adherence–enhancing strategies were management and reporting of drug-related symptoms and reminders to take medication, the importance of stakeholders’ engagement in intervention design, and the overall positive perceptions of delivery features. Areas for future research identified by this review include the need for further studies to evaluate the impact of mobile phone–delivered interventions on adherence to oral chemotherapy as well as the relevance for future studies to incorporate design frameworks and economic evaluations and to explore the moderator effect of high anxiety, poor baseline adherence, and longer time taking prescribed drug on adherence to oral chemotherapy.

Conclusions:

Despite the increasing body of evidence on the use of mobile phones to deliver medication adherence–enhancing interventions in chronic diseases, literature on the oral chemotherapy context is lacking. This review showed that existing interventions are highly acceptable and useful to cancer patients. The engagement of stakeholders as well as the use of a design framework are important elements in the development of mobile phone–delivered interventions that can be translated into oncology settings.


 Citation

Please cite as:

Skrabal Ross X, Gunn KM, Patterson P, Olver I

Mobile-Based Oral Chemotherapy Adherence–Enhancing Interventions: Scoping Review

JMIR Mhealth Uhealth 2018;6(12):e11724

DOI: 10.2196/11724

PMID: 30578182

PMCID: 6320412

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.